Loading stock data…
$3.75+0.02 (+0.54%)
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States.
Unicycive Therapeutics, Inc. in the Healthcare sector is trading at $3.75 with a market capitalization of $113M. Wall Street consensus targets $28.40 (10 analysts), implying a +657.3% move over the next 12 months. The stock is currently near its 52-week low of $3.67, remaining 39.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 16 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$10.14M↓ | -$8.44M↓ | -$7.22M↑ | -$7.34M↓ | -$6.96M |
| Net Income | -$1.72M↑ | -$12.82M↑ | -$14.67M↓ | -$6.01M↑ | -$6.45M |
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate bindin...